Ocala, FLNCT06187402Now EnrollingIRB Ready

Advanced Solid Tumors Clinical Trial in Ocala, FL

Access cutting-edge advanced solid tumors treatment through this phase 1/2 clinical trial at a research site in Ocala. Study-provided care at no cost to qualified participants.

Sponsored by LaNova Medicines Limited

Quick Self-Assessment

See if you qualify for this Ocala location

Preparing your pre-screening questions…

Expert Care in Ocala

Access advanced solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumors treatment provided free

Apply for This Ocala Location

Check if you qualify for this advanced solid tumors clinical trial in Ocala, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Ocala

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Ocala site if eligible
  4. 4Begin participation

About This Advanced Solid Tumors Study in Ocala

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

Sponsor: LaNova Medicines Limited

Who Can Participate

Inclusion Criteria

Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the informed consent form (ICF) prior to any study related procedures.
Aged ≥18 years old when sign the ICF, male or female.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and no deterioration within 2 weeks prior to the first dose.
Life expectancy ≥ 3 months.
Subjects must have histological or cytological confirmation of recurrent or refractory advanced solid tumors, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples meet the minimum requirements.
At least one measurable lesion according to RECIST v1.1.
Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion Criteria

Participate in any other clinical trial within 28 days prior to 1st dosing of LM-24C5.
Any prior treatments towards the investigational target.
Subjects with anti-tumor treatment within 21 days prior to 1st dosing of LM-24C5, including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy, etc. the following treatments have different time limits.
Any adverse event from prior anti-tumor therapy has not yet recovered to≤ grade 1 of CTCAE v5.0.
Subjects with uncontrolled pain.
Subjects with known central nervous system (CNS) or meningeal metastasis.
Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
Subjects who experienced grade 3 or higher hypersensitivity to the treatment that contains any monoclonal antibody.
Subjects who take systemic corticosteroids (\> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dosing of LM-24C5.
Subjects with the known history of autoimmune disease.
Subjects with the history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-24C5.
Subjects who are taking therapeutic doses of anticoagulants such as heparin or vitamin K antagonists for presence of active thromboembolic disease.
Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-24C5.
Subjects who have severe cardiovascular disease.
Subjects who have uncontrolled or severe illness, including but not limited to ongoing or active infection
Subjects who have a history of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, or organ transplantation, or allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation.
HIV infection, active infection including tuberculosis, HBV and HCV infection, with the exception:
Subjects who have other active malignancies which are likely to require the treatment.
Child-bearing potential female who have positive results in pregnancy test or are lactating.
Subjects who have psychiatric illness or disorders that may preclude study compliance.
Subject who is judged as not eligible to participate in this study by the investigator.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ocala?

Yes, this clinical trial (NCT06187402) has an active research site in Ocala, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumors Treatment Options in Ocala, FL

If you're searching for advanced solid tumors treatment options in Ocala, FL, this clinical trial (NCT06187402) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ocala research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Ocala, FL

See all advanced solid tumors clinical trials recruiting in Ocala — not just this study.

Browse Advanced Solid Tumors Trials in Ocala →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Ocala?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Ocala, FL